MétaCan
Menu
Back to cohort
Record W4238522628 · doi:10.4161/cbt.6.9.5034

Five New Research Programs to Receive Funding from the Samuel Waxman Cancer Research Foundation

2007· article· en· W4238522628 on OpenAlexaboutno aff

Bibliographic record

VenueCancer Biology & Therapy · 2007
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEpigenetics and DNA Methylation
Canadian institutionsnot available
Fundersnot available
KeywordsScope (computer science)Foundation (evidence)Political scienceLibrary scienceMedicineMedical educationManagementLawComputer science

Abstract

fetched live from OpenAlex

Abstract The Samuel Waxman Cancer Research Foundation (SWCRF) is pleased to announce the funding of five new investigative teams from John Hopkins University, The University of Rochester Medical Center, The Salk Institute for Biological Studies, The University of New Mexico, and The Wistar Institute in Philadelphia. This brings the total worldwide members of the Institute Without Walls to 60. SWCRF is unique in that the research programs it supports are both cancer type-specific and concept-driven, and researchers must agree to collaborate with their SWCRF peers on research projects funded by the Foundation. This worldwide collaborative approach to cancer research is the guiding principle of the Foundation's "Institute Without Walls". Dr. Samuel Waxman, professor of medicine at New York's Mount Sinai Medical Center, and Founder and Scientific Director of the Foundation, stated: "We are very pleased to expand the scope of our cancer research activities with the funding of these additional five new research initiatives. We know these worthwhile projects, in collaboration with our collective efforts over the years, will continue to improve the treatment and outcome of cancer patients." Prospective research teams submitted 70 detailed proposals for this highly selective and competitive process. All proposals were peer-reviewed, assessing the merits of the work and the potential for collaborative programs in epigenetic therapy, tumor dormancy and cancer stem cells. The final grantees are determined by utilizing the NIH scoring system. All funded programs are reviewed annually by an independent, external committee of eminent scientists. The following new research programs are being funded by SWCRF in 2007: - "Targeting the Sumoylation Machinery for the Relief of Gene Silencing and Differentiation Therapy" - Dr. Frank Rauscher, The Wistar Institute, Philadelphia. This is a basic control of epigenetic components and a good target for cancer selective therapy. - "Novel Therapies Targeting Epigenetic Silencing of Tumor Suppressors" - Dr. Robert A. Casero, Jr., Johns Hopkins Kimmel Cancer Center, (Project Leader), Dr. Stephen B. Baylin, Johns Hopkins Kimmel Cancer Center; Dr. Steven Belinsky, Lovelace Respiratory Research Institute of the University of New Mexico. A specific epigenetic component that malfunctions in colorectal cancer has been identified and inhibitors are being tested in this program. - "Pharmacogenetic Targeting of the Nuclear Hormone Receptors PPARdelta/gamma in Colorectal Cancer" - Dr. Ronald Evans, HHMI and The Salk Institute for Biological Studies. The nuclear receptor family called PPAR plays an important role in inflammation thought to play an important role in the development of colon cancer. - "MicroRNAs Regulating Acute Leukemia" - Dr. Curt Civin, Johns Hopkins Kimmel Cancer Center. AND - "Differentiation Therapy and Epigenetic Modulation of Human Leukemia Stem Cells" - Dr. Craig Jordan, University of Rochester Medical Center. Dr. Civin and Dr. Jordan will collaborate with others in the SWCRF to understand how to reprogram leukemia stem cells and eliminate the root cause of acute leukemia. About the Samuel Waxman Cancer Research Foundation Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy. Two drugs developed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL), which has helped cure 50,000 people. Since its inception, SWCRF has trained and supported more than 170 scientists with research grants exceeding $60 million. Based in New York City at The Mount Sinai Medical Center, the Foundation funds highly collaborative basic, translational and clinical research groups throughout the United States, Canada, China, Europe and Israel. SWCRF grant applicants are established investigators who agree to collaborate with other SWCRF investigators on research projects funded by the Foundation. Functioning as an "Institute Without Walls" the Foundation currently enables the collaboration of accomplished scientists in 35 different world-renown cancer research centers. SWCRF hosts international conferences that bring together differentiation therapy investigators in a major forum to share their findings with the scientific community. Foundation-supported projects are reviewed and evaluated annually by an independent external committee of eminent scientists. The Foundation derives most of its support from individual contributions. For more information, visit www.waxmancancer.org

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.553
Threshold uncertainty score0.998

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.215
GPT teacher head0.491
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueCancer Biology & TherapySame topicEpigenetics and DNA MethylationFrench-language works237,207